S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

iCAD Stock Forecast, Price & News

-0.05 (-1.25%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
97,075 shs
Average Volume
254,736 shs
Market Capitalization
$99.46 million
P/E Ratio
Dividend Yield
Price Target

iCAD MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
216.5% Upside
$12.50 Price Target
Short Interest
8.67% of Float Sold Short
Dividend Strength
News Sentiment
0.36mentions of iCAD in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.45 out of 5 stars

Computer And Technology Sector

572nd out of 936 stocks

Surgical & Medical Instruments Industry

101st out of 137 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ICAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCAD and its competitors with MarketBeat's FREE daily newsletter.

iCAD logo

About iCAD (NASDAQ:ICAD) Stock

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

ICAD Stock News Headlines

Analysts Set iCAD, Inc. (NASDAQ:ICAD) Target Price at $16.50
5 Growth Stocks to Buy Now - InvestorPlace
iCAD Announces CFO Transition - GlobeNewswire
iCAD Announces CFO Transition
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$-11.24 million
Pretax Margin


Sales & Book Value

Annual Sales
$33.64 million
Book Value
$1.85 per share


Free Float
Market Cap
$99.46 million

Social Links

iCAD Frequently Asked Questions

Should I buy or sell iCAD stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" iCAD stock.
View analyst ratings for iCAD
or view top-rated stocks.

What is iCAD's stock price forecast for 2022?

5 brokerages have issued 12-month price targets for iCAD's stock. Their ICAD stock forecasts range from $8.00 to $16.00. On average, they predict iCAD's share price to reach $12.50 in the next year. This suggests a possible upside of 216.5% from the stock's current price.
View analysts' price targets for iCAD
or view top-rated stocks among Wall Street analysts.

How has iCAD's stock performed in 2022?

iCAD's stock was trading at $7.20 at the beginning of the year. Since then, ICAD stock has decreased by 45.1% and is now trading at $3.95.
View the best growth stocks for 2022 here

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for iCAD

How were iCAD's earnings last quarter?

iCAD, Inc. (NASDAQ:ICAD) released its earnings results on Wednesday, May, 11th. The technology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. The technology company earned $7.52 million during the quarter, compared to the consensus estimate of $7.50 million. iCAD had a negative net margin of 40.43% and a negative trailing twelve-month return on equity of 26.45%.
View iCAD's earnings history

What guidance has iCAD issued on next quarter's earnings?

iCAD issued an update on its first quarter 2022 earnings guidance on Thursday, April, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $7.50 million-$7.50 million, compared to the consensus revenue estimate of $7.45 million.

Who are iCAD's key executives?

iCAD's management team includes the following people:
  • Ms. Stacey M. Stevens, Pres, CEO & Director (Age 54, Pay $366.35k) (LinkedIn Profile)
  • Mr. Jonathan Go, Chief Technology Officer (Age 59, Pay $330.13k) (LinkedIn Profile)
  • Mr. Stephen P. Sarno, Interim Chief Financial Officer (Age 55)
  • Ms. Annette L. Heroux, VP of Admin. (Age 65)
  • Mr. Anthony Takazawa, Director of Investor Relations
  • Brian Testa, Chief People Officer
  • Mr. Jeffrey Sirek, Chief Commercial Officer

What is Michael Klein's approval rating as iCAD's CEO?

4 employees have rated iCAD CEO Michael Klein on Glassdoor.com. Michael Klein has an approval rating of 75% among iCAD's employees.

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology (MRVL), NVIDIA (NVDA), Aptiv (APTV), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Ambarella (AMBA), BioXcel Therapeutics (BTAI) and Telefonaktiebolaget LM Ericsson (publ) (ERIC).

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $3.95.

How much money does iCAD make?

iCAD (NASDAQ:ICAD) has a market capitalization of $99.46 million and generates $33.64 million in revenue each year. The technology company earns $-11.24 million in net income (profit) each year or ($0.53) on an earnings per share basis.

How many employees does iCAD have?

iCAD employs 136 workers across the globe.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The official website for iCAD is www.icadmed.com. The technology company can be reached via phone at (603) 882-5200, via email at jeremy@lifesciadvisors.com, or via fax at 603-880-3843.

This page (NASDAQ:ICAD) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.